|
KMID : 1030220210220040259
|
|
Journal of Korean Diabetes
2021 Volume.22 No. 4 p.259 ~ p.267
|
|
|
2021 Clinical Practice Guidelines for Diabetes: Management of Cardiovascular Risk
|
|
Moon Min-Kyong
|
|
|
Abstract
|
|
|
|
The Committee of Clinical Practice Guidelines of the Korean Diabetes Association revised and updated the 7th Clinical Practice Guidelines in 2021. Intense multifactorial intervention including adequate control of glycemia, blood pressure, and low density lipoprotein cholesterol level and use of antiplatelet agents has been shown to reduce cardiovascular risk among patients with type 2 diabetes mellitus. In these recent guidelines, sodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors) and glucagon-like peptide 1 receptor agonists (GLP-1 RAs) with proven benefits were recommended in patients with heart failure and/or atherosclerotic cardiovascular disease (ASCVD) as mono- or combination therapy. SGLT2 inhibitors such as dapagliflozin, empagliflozin, and ertugliflozin were recommended preferentially in patients with heart failure. In those with ASCVD, treatment including SGLT2 inhibitors such as empagliflozin and dapagliflozin or GLP-1 RAs such as dulaglutide, liraglutide, and semaglutide as a combination therapy was recommended.
|
|
|
KEYWORD
|
|
|
Cardiovascular disease, Diabetes mellitus, type 2, Drug therapy, Practice guideline
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|